The episodic GnRH release from the hypothalamic GnRH pulse generator, controlled by excitatory and inhibitory neurotransmitters as well as neuropeptides and glial factors, induces the pulsatile ...
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, ...
The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist for adults with advanced prostate cancer is now available in clinical practice. On December 18, 2020, the FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results